VKTX - Viking Therapeutics Inc Options
This article provides a detailed financial overview of Viking Therapeutics Inc (VKTX), including its last closing price, market capitalization, key financial ratios, and performance metrics. It also lists insider ownership and transactions, institutional ownership, and short interest data, alongside various price performance indicators for different periods. The data presented covers the company's stock activity, earnings per share, sales, and analyst recommendations.
Is Viking Therapeutics Stock Going to $100?
Viking Therapeutics is a clinical-stage biotech company with promising weight-loss drug candidates, particularly VK2735, which mimics GLP-1 and GIP hormones. The company is undergoing Phase 3 trials for VK2735 and developing an oral formulation, with potential for its stock to reach $100 by late 2027 if trials are successful. However, as a clinical-stage company with binary trial outcomes, it carries significant risk for investors, and positive results are critical for stock appreciation.
Why Viking Therapeutics (VKTX) Is Up 22.2% After Advancing VK3019 Into First-in-Human Obesity Trial
Viking Therapeutics' stock rose 22.2% after it advanced VK3019, a new obesity treatment, into a Phase 1 clinical trial following FDA clearance. This move expands Viking's metabolic disease pipeline, complementing its late-stage VK2735 program and aiming to build a diverse obesity treatment franchise. Despite this advancement, the company's investment narrative still heavily relies on successful Phase 3 readouts for VK2735 and faces risks from high R&D spend without commercial revenue.
Viking Therapeutics (VKTX) Starts A Phase 1 Obesity Trial, Is The Upside Already Priced In?
Viking Therapeutics (VKTX) has commenced a Phase 1 trial for VK3019, its new dual amylin and calcitonin receptor agonist targeting obesity, sparking investor interest as the stock has already seen significant gains. Despite a strong market run with shares up over 5x in five years, the prevailing narrative suggests the stock is 59% undervalued with a fair value of $92.72, primarily due to high expectations for its obesity pipeline, including VK2735. However, the company faces risks related to high R&D spend and potential shareholder dilution if further equity raises are needed, and its current P/B ratio is significantly above the industry average.
ETFs Investing in Viking Therapeutics, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Viking Therapeutics, Inc. The ETFs are sorted by their market value dedicated to Viking Therapeutics, Inc. and include details like the ETF's issuer, management style, focus, expense ratio, assets under management (AUM), and historical performance.
Enterprise value to EBITDA forward of Viking Therapeutics, Inc. – NASDAQ:VKTX
This article focuses on the enterprise value to EBITDA forward for Viking Therapeutics, Inc. (NASDAQ: VKTX) as observed on TradingView. It appears to be a stub or a section of a larger financial data presentation, providing a specific financial metric for the company. The content primarily lists navigation and structural elements typical of a financial data platform.
Enterprise value to EBIT forward of Viking Therapeutics, Inc. – NASDAQ:VKTX
The article focuses on the enterprise value to EBIT forward for Viking Therapeutics, Inc. (NASDAQ: VKTX) and provides financial data for the company. It serves as a financial information page on TradingView, listing various related metrics and offering general market data without a detailed analysis.
Viking Therapeutics Expands Obesity Pipeline With VK3019 Phase 1
Viking Therapeutics has initiated a Phase 1 trial for VK3019, a dual amylin and calcitonin receptor agonist, broadening its obesity treatment pipeline. This new candidate could complement existing GLP-1 therapies like VK2735, which is currently in Phase 3 trials for both subcutaneous and oral formulations. Analysts maintain a "Buy" rating on Viking Therapeutics, highlighting the company's diversified pipeline and the potential of its various metabolic disorder treatments.
A New Obesity Drug Just Reached Human Trials. Here's What Comes Next
Viking Therapeutics Inc. (VKTX) has initiated a Phase 1 clinical trial for VK3019, an investigational weight-loss drug, after FDA clearance. This dual amylin and calcitonin receptor agonist demonstrated promising preclinical results in reducing body weight and food intake. Analysts at H.C. Wainwright & Co. have reiterated a "Buy" rating for Viking, citing a strong obesity pipeline and upcoming clinical milestones for VK3019 and VK2735.
Price to sales forward of Viking Therapeutics, Inc. – FWB:1VT
This page provides financial information for Viking Therapeutics, Inc. (FWB:1VT) on the Frankfurt Stock Exchange, specifically focusing on its forward price-to-sales ratio. It details that the market is currently closed with no trades, and the content was "made by humans."
Is Viking Therapeutics Poised to Disrupt the Weight-Loss Market
Viking Therapeutics, a clinical-stage biotech company, is emerging as a significant player in the weight-loss drug market with its lead candidate, VK2735. This dual GLP-1/GIP agonist, which has both subcutaneous and oral formulations, shows promising efficacy in weight reduction and aims to compete with established pharmaceutical giants like Eli Lilly and Novo Nordisk. Despite strong analyst confidence and a robust pipeline including VK2809 for NASH, the company faces intense competition and inherent risks associated with clinical development and regulatory hurdles.
Viking Therapeutics Starts Human Clinical Trials For New Obesity Drug Following Federal Regulatory Clearance
Viking Therapeutics has begun a Phase 1 clinical trial for VK3019, an experimental weight-loss drug, following FDA clearance. This new drug targets amylin and calcitonin receptors, differentiating it from GLP-1 agonists like Ozempic. The company is also advancing its lead drug VK2735, with Phase 3 trials underway and plans for an oral version, indicating a robust pipeline for the growing obesity treatment market.
Viking Therapeutics (VKTX) Starts First Human Obesity Trial For VK3019
Viking Therapeutics has initiated a Phase 1 clinical trial for VK3019, a dual amylin and calcitonin receptor agonist for obesity, expanding its metabolic disorder pipeline beyond existing GLP-1/GIP candidates. This diversification provides an additional therapeutic mechanism in the competitive obesity treatment landscape, which includes major players like Eli Lilly and Novo Nordisk. While this is an early step focused on safety, it signals the company's strategy to develop multiple approaches for obesity, though it also increases R&D costs for the clinical-stage company.
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
Viking Therapeutics has initiated a Phase 1 clinical study for VK3019, a novel dual amylin and calcitonin receptor agonist (DACRA), designed to evaluate its safety, tolerability, and pharmacokinetics in healthy adults for potential weight loss treatment. This move expands Viking's portfolio, which also includes the Phase 3 VANQUISH studies for VK2735 (a dual GLP-1/GIP agonist) and an oral formulation of VK2735. The company aims to provide diverse treatment options for obesity and metabolic disorders, leveraging both injectable and oral formulations to enhance patient adherence and long-term weight management.
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
Viking Therapeutics has initiated a Phase 1 clinical trial for VK3019, a novel dual amylin and calcitonin receptor agonist (DACRA), as a potential treatment for weight loss. The study will evaluate the safety, tolerability, and pharmacokinetics of VK3019 in healthy adults. This move expands Viking's pipeline, which also includes the ongoing Phase 3 VANQUISH studies for VK2735 for obesity and overweight, and an oral formulation of VK2735 currently in development.
Viking Therapeutics begins phase 1 trial of weight loss drug
Viking Therapeutics announced the start of a Phase 1 clinical trial for VK3019, an investigational dual amylin and calcitonin receptor agonist for weight loss, which caused its stock to surge. The randomized, double-blind, placebo-controlled study will evaluate single ascending doses in healthy adults with a BMI of 30 or higher, assessing safety, tolerability, pharmacokinetics, and exploratory body weight changes. This news comes as the company also progresses with Phase 3 trials for another weight-loss drug, VK2735, and has received positive analyst ratings.
Viking Therapeutics (VKTX) Soars Higher — Medicare Could Hold The Answer
Viking Therapeutics (VKTX) stock surged for an eighth consecutive day, driven by investor interest in the weight loss market due to Medicare's upcoming coverage of anti-obesity treatments starting July 1, 2026. The company is developing its own obesity and type 2 diabetes drug, VK2735. Additionally, Viking Therapeutics announced the appointment of Hubert Chen as its new chief medical officer, who will oversee clinical development, medical, and regulatory affairs.
VKTX Stock Grinds Higher As Wall Street Boosts Obesity Bets
Viking Therapeutics (VKTX) stock has risen by 7.54% due to promising obesity drug trial data, attracting increased Wall Street optimism. Several firms like Truist and Lake Street have initiated "Buy" ratings and high price targets, driven by the potential of VKTX's obesity drug VK2735. The company recently appointed a new CMO to steer late-stage programs, and upcoming meetings with financial institutions are expected to provide further catalysts for the stock.
Viking Therapeutics Inc (VKTX) Financial Health: Profitability & Balance Sheet Analysis
This article provides a financial health analysis of Viking Therapeutics Inc (VKTX), stating its current financial score is 3.80, ranking 389 out of 389 in the Biotechnology & Medical Research industry, indicating a weak financial status and low operating efficiency. The analysis highlights that relevant data for various financial dimensions such as Cash and cash equivalents, Total revenue, Operating profit, and Free cash flow have not been disclosed by the company yet.
Mid-Cap Biotech Viking Therapeutics Could Emerge as a Potential Challenger to Eli Lilly and Novo Nordisk
Viking Therapeutics is positioning itself as a challenger in the anti-obesity drug market, currently dominated by Eli Lilly and Novo Nordisk. Their lead candidate, VK2735, has shown promising early-stage data with both injectable and oral forms, suggesting significant weight loss. Although facing strong competition from the pipelines of the established giants, Viking's potential remains optimistic if later-stage trials confirm initial results, potentially shifting the market landscape.
Does Viking Therapeutics (VKTX) New CMO Hire Reveal a Deeper Metabolic Ambition?
Viking Therapeutics (VKTX) recently appointed Hubert C. Chen, M.D., as Chief Medical Officer, a move that aligns with the company's focus on VK2735 and broader metabolic programs, particularly in obesity and type 2 diabetes. Dr. Chen's extensive experience in regulatory strategy and metabolic diseases is expected to help Viking Therapeutics navigate clinical and regulatory hurdles for its oral formulation moving towards Phase III trials. The company's investment narrative hinges on the success of VK2735, with forecasts predicting significant revenue and earnings by 2029, suggesting a substantial upside to its current stock price.
Viking Therapeutics (VKTX) Stock Could Be 67.2% Undervalued After Analysts Back VK2735
Viking Therapeutics (VKTX) stock is considered 67.2% undervalued by analysts, driven by the potential of its obesity drug candidate VK2735 and the recent appointment of a new chief medical officer. Despite a 14.23% year-to-date decline, the stock has shown a 351.41% return over five years. The fair value estimate of $92.72 largely depends on the successful development and market penetration of VK2735, especially its flexible subcutaneous and oral formulations.
Viking Therapeutics (VKTX) Stock Could Be 67.2% Undervalued After Analysts Back VK2735
Viking Therapeutics (VKTX) stock is considered 67.2% undervalued by analysts, trading at $30.38 against a fair value of $92.72, primarily due to the potential of its obesity drug candidate VK2735. The company recently appointed a new chief medical officer to support its clinical ambitions, and is progressing with subcutaneous and oral formulations of VK2735, including plans for Phase III oral trials. However, the article notes that its P/B ratio of 7x is higher than industry averages, indicating potential valuation risk if expectations aren't met or if trial results disappoint.
Liquidity Mapping Around (VKTX) Price Events
This article from Stock Traders Daily provides a liquidity mapping analysis for Viking Therapeutics Inc. (NASDAQ: VKTX). It highlights divergent sentiment readings, suggesting choppy conditions, and offers three AI-generated institutional trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, each tailored to different risk profiles. The analysis also includes multi-timeframe signal analysis with immediate, mid-term, and long-term support and resistance levels.
Viking Therapeutics (VKTX) Offers Potential With VK2735 Market Opportunity
Lake Street and Truist Securities have assigned Buy ratings to Viking Therapeutics (VKTX), citing the significant market opportunity for its lead clinical asset VK2735, a treatment for obesity. Analysts project VK2735 could generate $3 billion in risk-adjusted worldwide sales by 2040 and highlight VKTX's advantage in addressing patient compliance and speed to efficacy with both oral and subcutaneous delivery options. The company specializes in therapies for metabolic and endocrine disorders.
Is Viking’s New CMO Appointment Reframing the VK2735 Investment Case for Viking Therapeutics (VKTX)?
Viking Therapeutics recently appointed Hubert C. Chen, M.D., as Chief Medical Officer, a move expected to strengthen the clinical and regulatory leadership for its VK2735 obesity drug. Although his appointment provides experienced oversight for critical late-stage trials, it doesn't change the near-term catalysts or core risks associated with VK2735's success. The company's investment narrative still hinges on VK2735 clearing trials, with key data anticipated later this year, amid ongoing high R&D spend and net losses.
Viking Therapeutics Adds New CMO As Pipeline Progress And Valuation Scrutinized
Viking Therapeutics has appointed Dr. Hubert C. Chen as Chief Medical Officer, bringing extensive experience to the company's metabolic and endocrine therapy pipeline. This appointment is significant for investors, as it may influence future clinical programs, regulatory engagement, and resource allocation. While the stock trades significantly below analyst expectations, Simply Wall St's valuation suggests it's currently overpriced, and the company remains unprofitable with no meaningful revenue.
Is Viking’s New CMO Appointment Reframing the VK2735 Investment Case for Viking Therapeutics (VKTX)?
Viking Therapeutics recently appointed Hubert C. Chen, M.D., as Chief Medical Officer, bringing extensive experience in clinical development and regulatory affairs, particularly in obesity and GLP-1/GIP programs. While this strengthens the company's leadership for its critical late-stage VK2735 trials, it does not fundamentally alter the investment narrative or near-term catalysts, which still hinge on successful Phase III readouts for its injectable and oral obesity treatments. Investors should continue to monitor trial progress and the company's financial health given high R&D spending and ongoing net losses.
Viking Therapeutics Adds New CMO As Pipeline Progress And Valuation Scrutinized
Viking Therapeutics (NasdaqCM:VKTX) has appointed Dr. Hubert C. Chen as Chief Medical Officer, bringing extensive experience in drug discovery and clinical development as the company progresses its pipeline of metabolic and endocrine therapies. This appointment is significant for shaping the company's clinical programs and regulatory strategies, and investors will be watching how his leadership impacts upcoming trials and development timelines. Despite the positive leadership change, Simply Wall St's analysis flags the stock as trading at a rich valuation, approximately 273% above its estimated fair value.
Viking Therapeutics Taps Hubert Chen as Chief Medical Officer
Viking Therapeutics has appointed Hubert C. Chen, MD, as its new Chief Medical Officer. Chen will be responsible for overseeing clinical development, medical, and regulatory affairs, reporting directly to President and CEO Brian Lian, PhD. His extensive background includes leadership roles at Loyal Animal Health, Forte Biosciences, Metacrine, and Pfenex, with significant experience in drug discovery, clinical development, and regulatory strategies for metabolic and endocrine disorders.
Viking Therapeutics appoints Hubert Chen as chief medical officer By Investing.com
Viking Therapeutics (NASDAQ:VKTX) has appointed Hubert C. Chen, M.D., as its new chief medical officer. Dr. Chen brings over 20 years of experience in drug discovery and development, and will oversee clinical development, medical, and regulatory affairs. The company is currently advancing its VK2735 program for obesity, with both subcutaneous and oral formulations in clinical trials, and holds a market capitalization of $3.22 billion.
Viking Therapeutics, Inc. (VKTX) falls more steeply than broader market: What investors need to know
This article from MSN discusses how Viking Therapeutics, Inc. (VKTX) experienced a steeper decline than the overall market. It aims to inform investors about the significance of this performance. The full article content was not provided, so further details are unavailable.
Viking Therapeutics Announces Appointment Of Hubert C. Chen, M.D., As Chief Medical Officer
Viking Therapeutics has announced the appointment of Hubert C. Chen, M.D., as its new Chief Medical Officer. The article, sourced from Reuters via Refinitiv, is a brief update on this executive change at Viking Therapeutics (VKTX).
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
Viking Therapeutics, Inc. has appointed Hubert C. Chen, M.D., as its new Chief Medical Officer, bringing over two decades of experience in drug development and regulatory strategy. Dr. Chen will oversee clinical development, medical, and regulatory affairs as Viking advances its late-stage therapies, including VK2735 for obesity and VK2809 for NASH. His expertise in metabolic and endocrine disorders is expected to be crucial for the company's expanding pipeline.
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
Viking Therapeutics, Inc. (VKTX) closed down 5.13%, underperforming the broader market and the Medical sector. Over the past month, its shares depreciated by 6.67%. Upcoming earnings projections indicate a significant decrease in EPS, and VKTX currently holds a Zacks Rank of #3 (Hold).
Why (VKTX) Price Action Is Critical for Tactical Trading
This article analyzes Viking Therapeutics Inc. (NASDAQ: VKTX) with a focus on tactical trading strategies. It highlights a weak near-term sentiment that could lead to bearish positioning, but also identifies support being tested and an exceptional risk-reward setup targeting an 18.5% gain. The piece presents AI-generated trading strategies for different risk profiles, including position, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis.
ETFs Investing in Viking Therapeutics, Inc. Stocks
This article lists various ETFs that hold shares of Viking Therapeutics, Inc. (1VT) and provides detailed data for each fund, including market value, weight of 1VT stock, issuer, management style, focus, expense ratio, AUM, price, change, relative volume, and 3-year NAV total return. The ETFs listed cover a range of investment focuses, including small cap, health care, and biotech, offering different ways for investors to gain exposure to Viking Therapeutics, Inc. stocks.
Current ratio of Viking Therapeutics, Inc. – XETR:1VT
This article provides financial information for Viking Therapeutics, Inc. (XETR:1VT), specifically focusing on its current ratio. The content is presented within the TradingView platform, offering an overview of the company's financials.
Asset turnover of Viking Therapeutics, Inc. – XETR:1VT
This page from TradingView displays the asset turnover for Viking Therapeutics, Inc. (XETR:1VT). It includes financial data, overview, news, community, and forecast sections for the company. The page also mentions that the market is closed with no recent trades.
Basic earnings per share (basic EPS) of Viking Therapeutics, Inc. – XETR:1VT
The article focuses on the basic earnings per share (basic EPS) for Viking Therapeutics, Inc. (XETR:1VT). It presents financial data related to the company's EPS, including period, value, and change percentages. The information is presented within the TradingView platform, with data provided by ICE Data Services and FactSet.
A Look At Viking Therapeutics (VKTX) Valuation As VK2735 Obesity Drug Progress Draws Investor Attention
Viking Therapeutics (VKTX) is attracting investor attention due to upcoming clinical catalysts for its obesity drug VK2735, with Phase 1 maintenance trial results expected in Q3 2026. Despite a 16% year-to-date share price drop, a Simply Wall St narrative suggests the stock is 67.9% undervalued at a fair value of $92.72, driven by ambitious obesity drug expectations. However, a contrasting view highlights the stock's high P/B ratio of 6.9x compared to peers, raising concerns about valuation risk.
A Look At Viking Therapeutics (VKTX) Valuation As VK2735 Obesity Drug Progress Draws Investor Attention
Viking Therapeutics (VKTX) is under investor scrutiny due to its obesity drug VK2735, with Phase 1 trial results expected in Q3 2026. Despite a 16% year-to-date share price drop, the company's valuation narrative suggests it is significantly undervalued at $29.78 compared to a fair value of $92.72, driven by ambitious expectations for its obesity drug. However, the market currently prices VKTX on a higher P/B ratio than peers, indicating potential valuation risk amidst heavy R&D spending and ongoing net losses.
InvestingPro’s overvalued call on Viking Therapeutics saves investors 41% By Investing.com
InvestingPro accurately predicted that Viking Therapeutics (VKTX) was significantly overvalued in June 2024 when its stock was trading at $50.64. Over the subsequent two years, the stock declined by 41% to $29.76, confirming InvestingPro's Fair Value analysis which had calculated an intrinsic value of $32.52. This case highlights the utility of systematic valuation analysis in helping investors avoid losses or profit from shorting overvalued assets.
Viking Therapeutics Nears VK2735 Milestones As Valuation Signals Mixed Picture
Viking Therapeutics is nearing key milestones for its VK2735 obesity drug, including a Q3 maintenance trial data readout and the planned start of a pivotal oral formulation study. Despite significant long-term stock gains, the share price is down year-to-date and trades at a premium to Simply Wall St's estimated fair value, presenting a mixed picture for investors as critical clinical trial results approach. The market's reaction to these upcoming data points will be crucial, especially given the company's current lack of revenue.
Viking Therapeutics Inc at Jefferies Global Healthcare Conference in New York Transcript
Viking Therapeutics Inc participated in the Jefferies Global Healthcare Conference in New York, with President and CEO Brian Lian, CFO Greg Zante, and Chief Commercial Officer Neil Aubuchon present. During the discussion moderated by Roger Song of Jefferies LLC, Brian Lian provided an overview of the company's activities, highlighting its obesity program which is currently in Phase III development with two ongoing trials, VANQUISH-1 and VANQUISH-2.
Viking Therapeutics Nears VK2735 Milestones As Valuation Signals Mixed Picture
Viking Therapeutics (NasdaqCM:VKTX) is approaching key milestones for its obesity drug VK2735, including Q3 maintenance trial data and the start of a pivotal oral formulation study. While the stock has seen significant long-term gains, recent performance has been negative, and Simply Wall St's valuation suggests it trades well above its estimated fair value. Investors are advised to monitor the clinical trial outcomes carefully, given the company's lack of revenue and ongoing losses.
Viking Therapeutics (NASDAQ: VKTX) Chief Medical Officer named insider in Form 3 filing
Viking Therapeutics (NASDAQ: VKTX) has reported that its Chief Medical Officer, Chen Hubert C, was named an insider in a new Form 3 filing. This administrative filing establishes his status as an insider for future reporting requirements but does not indicate any transactions or beneficial ownership of securities at this time. The Form 3 confirms his role as Chief Medical Officer and indicates no derivative securities or share movements.
Viking Therapeutics (NASDAQ: VKTX) CMO awarded 190,000 stock options
Viking Therapeutics' Chief Medical Officer, Hubert C. Chen, has been granted 190,000 stock options. The options have an exercise price of $31.27 per share and an expiration date of June 1, 2036. The vesting schedule includes an immediate 25% vesting, with the remaining 75% vesting over the next three years at 25% annually.
Bull vs. Bear: The Quick Take on Viking Therapeutics Stock
This article discusses the "bull vs. bear" case for Viking Therapeutics (VKTX), focusing on its experimental weight-loss drug, VK2735. While competitors Eli Lilly and Novo Nordisk already have established oral weight-loss drugs, Viking's drug shows promise due to its steeper velocity of weight loss in trials and its dual-formulation therapy. However, the bear case highlights Viking's lag behind larger rivals and the need for improved tolerability data for its oral VK2735 in Phase 3 trials.
We Think Viking Therapeutics (NASDAQ:VKTX) Needs To Drive Business Growth Carefully
This article analyzes Viking Therapeutics' (NASDAQ:VKTX) financial health, focusing on its lack of profitability and the substantial cash burn, which raises questions about its long-term viability without securing additional funding or achieving a significant clinical breakthrough. Despite a strong cash position that could last two years, the company's reliance on external financing and successful drug development underscores the high risks involved. The analysis suggests caution for investors due to the company's current stage of development and financial trajectory.
